{'fraction_non_alphanumeric': 0.03595658073270014, 'fraction_numerical': 0.018317503392130258, 'mean_word_length': 6.266009852216749, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 1, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mouse recombinant phenylalanine monooxygenase and the S‐oxygenation of thioether substrates

The substrate specificity of mouse recombinant phenylalanine monooxygenase (mPAH) has been investigated with respect to the mucoactive drug, S‐carboxymethyl‐L‐cysteine (SCMC) and its thioether metabolites. Phenylalanine monooxygenase was shown to be able to catalyze the S‐oxygenation of SCMC, its decarboxylated metabolite, S‐methyl‐L‐cysteine and both their corresponding N‐acetylated forms. However, thiodiglycolic acid was found not to be a substrate. The enzyme profiles for both phenylalanine and SCMC showed Michaelis‐Menten with noncompetitive substrate inhibition for both the substrate‐activated and the lysophosphatidylcholine‐activated mPAH assays. The tetrameric enzyme was shown to undergo posttranslational activation by preincubation with substrate, lysophosphatidylcholine, N‐ethylmaleimide (a thiol alkylating agent), and the proteolytic enzymes α‐chymotrypsin and trypsin. Similar posttranslational activation of PAH activity in the rat and human has also been reported. These results suggest that in the mouse, PAH was responsible for the S‐oxidation of SCMC and that the mouse models of the hyperphenylalaninemias may be a potential tool in the investigation of the S‐oxidation polymorphism in man. © 2009 Wiley Periodicals, Inc. J Biochem Mol Toxicol 23:119–124, 2009; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jbt.20274